Exenatide (Byetta) for Gastroparesis
|11,247 Patients Studied||37 Studies (View)|
Definition: Exenatide (marketed as Byetta) is a medication approved (Apr 2005) for the treatment of diabetes mellitus type 2. It is manufactured by Amylin Pharmaceuticals and Eli Lilly and Company. Exenatide is administered as a subcutaneous injection (under the skin) of the abdomen, thigh, or arm, any time within the 60 minutes before the first and last meal of the day. Gastroparesis, also called delayed gastric emptying, is a medical condition consisting of a paresis of the stomach, resulting in food remaining in the stomach for a longer period of time than normal. Normally, the stomach contracts to move food down into the small intestine for digestion. The vagus nerve controls these contractions. Gastroparesis may occur when the vagus nerve is damaged and the muscles of the stomach and intestines do not work normally. (SOURCE: Wikipedia)
Where does Exenatide (Byetta) rank compared to other Gastroparesis treatments?
Health experts published 43 studies on Enteral Nutrition and Gastroparesis making Enteral Nutrition the #12 most researched treatment. In research involving Gastroparesis, experts have concluded that Enteral Nutrition is effective in 4 studies and safe in 2 studies.
#14Health experts published 59 studies on Gastrectomy and Gastroparesis making Gastrectomy the #14 most researched treatment. In research involving Gastroparesis, experts have concluded that Gastrectomy is effective in 2 studies and safe in 2 studies.
What peer treatments do patients prefer?
What does the FDA say about side effects?
Most Researched Conditions
What other conditions have been studied?
What treatments have patients discontinued using?
What treatments are patients switching to?